1.82
-0.03(-1.62%)
Currency In USD
Address
131 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
415 231 5660
Website
Sector
Healthcare
Industry
Biotechnology
Employees
241
First IPO Date
February 07, 2019
| Name | Title | Pay | Year Born |
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, Chief Executive Officer & Director | 1.06M | 1956 |
| Dr. Marc Grasso M.D. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 728,714 | 1974 |
| Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer | 752,171 | 1962 |
| Dr. Saraswati Kenkare-Mitra Ph.D. | President and Head of Research & Development | 1.29M | 1968 |
| Ms. Clare Hunt M.B.A. | Chief People Officer | 0 | N/A |
| Ms. Norah Conway | Senior Vice President of Portfolio & Program Management | 0 | N/A |
| Ms. Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy | 0 | N/A |
| Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel | 0 | N/A |
| Ms. Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer | 0 | N/A |
| Ms. Katie Hogan | Senior Director of Corporate Communication & Investor Relations | 0 | N/A |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.